Benign prostatic hyperplasia: a progressive disease of aging men

By Emberton M.   Andriole G.L.   de la Rosette J.   Djavan B.   Hoefner K.   Vela Navarrete R.   Nordling J.   Roehrborn C.   Schulman C.   Teillac P.   Tubaro A.   Nickel J.C.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 267-273

Elsevier

Access to resources Recommend Favorite

Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting

By Keetch D.W.   Andriole G.L.   Ratliff T.L.   Catalona W.J.  

Urology, Vol. 50, Iss. 6, 1997-12 ,pp. : 901-905

Elsevier

Access to resources Recommend Favorite

Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia

By Kaplan S.A.   Holtgrewe H.L.   Bruskewitz R.   Saltzman B.   Mobley D.   Narayan P.   Lund R.H.   Weiner S.   Wells G.   Cook T.J.   Meehan A.   Waldstreicher J.   for the Proscar Long-Term Efficacy and Safety Study Group  

Urology, Vol. 57, Iss. 6, 2001-06 ,pp. : 1073-1077

Elsevier

Access to resources Recommend Favorite

Medical therapy for asymptomatic men with benign prostatic hyperplasia: primum non nocere

By Kaplan S.A.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 784-785

Elsevier

Access to resources Recommend Favorite

Treatment of men with minimally symptomatic benign prostatic hyperplasia-PRO: the argument in favor

By Marks L.S.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 781-783

Elsevier

Access to resources Recommend Favorite